Minerva Neurosciences, Inc. (NERV)
NASDAQ: NERV · Real-Time Price · USD
4.200
+0.160 (3.96%)
At close: Oct 31, 2025, 4:00 PM EDT
4.140
-0.060 (-1.43%)
After-hours: Oct 31, 2025, 7:45 PM EDT
Minerva Neurosciences Employees
Minerva Neurosciences had 8 employees as of December 31, 2024. The number of employees decreased by 1 or -11.11% compared to the previous year.
Employees
8
Change (1Y)
-1
Growth (1Y)
-11.11%
Revenue / Employee
n/a
Profits / Employee
$1,403,700
Market Cap
29.37M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8 | -1 | -11.11% |
| Dec 31, 2023 | 9 | 0 | - |
| Dec 31, 2022 | 9 | 0 | - |
| Dec 31, 2021 | 9 | -2 | -18.18% |
| Dec 31, 2020 | 11 | -2 | -15.38% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NERV News
- 11 days ago - Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved - GlobeNewsWire
- 2 months ago - Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results - GlobeNewsWire
- 6 months ago - Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 8 months ago - Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates - GlobeNewsWire
- 1 year ago - Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates - GlobeNewsWire
- 1 year ago - Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates - GlobeNewsWire
- 1 year ago - US FDA declines to approve Minerva Neurosciences' schizophrenia drug - Reuters
- 1 year ago - Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates - GlobeNewsWire